As a primary point of contact for patients, the role of the nurse is pivotal to the continuum of care. While this can be true for any patient, it is especially true for hematology patients undergoing immunotherapy.
In supporting the patient or caregiver, the nurse will assist countless times throughout the course of the patient journey. This assistance can take many forms, including discussions on disease-management options, consent, treatment, identification and monitoring of adverse events, and coordination of the multidisciplinary team. Because treatments are often administered in regional specialized centers, isolation and anxiety can add to an already uncertain future caused by a poor prognosis: The nurse becomes the patient's compass and ensures a comprehensive approach to a complex situation.
By giving more nurses greater access to the specialized immunotherapy knowledge and skills needed to actively role manage their patients, and by creating an online environment that nurtures a transparent exchange of ideas, information, and intelligence, we are helping more nurses to make a difference. We believe medical education should be for everyone.
Introduction to immunotherapy: What nurses need to know about emerging therapies
Understanding these rapidly evolving treatments will help you advocate for patients and manage side effects.
Blinatumomab use in pediatric ALL: Taking a BiTE out of preparation, administrat...
The purpose of this paper is to discuss practical considerations for safe blinatumomab delivery from the pharmacy and nursing perspectives.
CAR T-Cell Therapy Is Active, Safe in ALL
Since the publication of the pivotal ELIANA trial in pediatric patients with acute lymphoblastic leukemia, the field of CAR T-cell therapy has grown significantly and left providers better equipped to understand and manage treatment-related adverse effects, such as cytokine release syndrome.
Oncology Nursing News: CAR T-Cell Therapy Is Promising in Myeloma
Autologous and allogeneic BCMA-directed CAR T-cell therapies are leading to deep and durable responses in patients with heavily pretreated multiple myeloma, with a low incidence of severe cytokine release syndrome (CRS) and neurotoxicity, explained Yi Lin, MD, PhD, who added that with a pending biologics license application (BLA), the field should start to consider which patients, who don’t fit the typical clinical trial eligibility criteria, might be a candidate for the treatment in real-world practice.
Episode 139: How CAR and Other T Cells Are Revolutionizing Cancer Treatment
ONS member Cecily Snyder, BSN, RN, OCN®, BMTCN®, transplant case manager of the blood and marrow transplantation program at Nebraska Medicine in Omaha and member of the Metro Omaha ONS Chapter, joins Stephanie Jardine, BSN, RN, oncology clinical specialist at ONS, to discuss T-cell therapy and how it’s changed approaches to cancer treatment and patient management for oncology nurses.
The Post-EBMT/CAR-T Nursing Session from VJHemOnc
With leading experts, Erik Aerts, John Murray, Michelle Kenyon & Rose Ellard. Register now and learn more about key updates in oncology nursing from the recent EBMT/CAR-T meeting. Topics discussed include: Highlights from EBMT/CAR-T, establishing a multidisciplinary CAR-T communication board, immune cell therapies in solid tumors, treatment settings, how to support multidisciplinary teams, palliative care - when to introduce?, future of CAR-T therapies.
The role of the coordinator nurse in the CAR-T treatment
In this video, Marlene Vercasson, from the Lyon Hospital, shares her experience in the local CAR-T program and Juliet international clinical trial. She reviews the many tasks appointed to the coordinator nurse, in adapting care to the individual patient and making contacts with the Apheresis department, Tissue and Cells Bank, Hematology...
Do mAbs and paraprotein affect COVID-19 Serological Testing in Patients with Mul...
SARS-CoV-2 (COVID-19) serology tests do not appear to interfere or cause cross-reactivity with therapeutic monoclonal antibody (t-mAb) treatments for hematologic malignancies (HM) such as multiple myeloma (MM), according to a study published in Diagnostics.
CAR T-Cell Therapy Improves Blood Cancer, But Toxicities Are Still Concerning
In an interview with OncLive, during the 2020 Institutional Perspectives in Cancer webinar on Leukemia and Lymphoma, Olalekan O. Oluwole, MBBS, MD, who is an assistant professor of medicine, hematology, and oncology at Vanderbilt-Ingram Cancer Center, highlighted the evolution of CAR T-cell therapy in leukemia and lymphoma, targets under investigation, and next steps for exploration.
Promising Response Rates Build Excitement for CAR T-Cell Therapy in Myeloma
Anwer, an oncologist, physician-scientist, and stem cell transplant staff physician at the Taussig Cancer Center of Cleveland Clinic, discussed the growing role of CAR T-cell therapy in multiple myeloma and areas of unmet need.